| human | Q5 |
| P496 | ORCID iD | 0000-0002-9301-5951 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q100313125 | 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy |
| Q47881329 | A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer |
| Q91526775 | A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer |
| Q57115139 | A Systematic Review and Pooled Analysis of Studies of Oral Etoposide in Metastatic Breast Cancer |
| Q34220013 | A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes |
| Q92067685 | A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer |
| Q103020289 | A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma |
| Q38927413 | A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer |
| Q27499174 | AFP-producing hepatoid adenocarcinoma of the stomach: a case report |
| Q38074758 | Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole |
| Q35055782 | Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature |
| Q39714162 | Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. |
| Q91066783 | Adherence to guidelines for baseline staging in newly diagnosed localized breast cancer |
| Q40439729 | Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. |
| Q101469916 | Amplification of 8p11.23 in cancers and the role of amplicon genes |
| Q92909810 | Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry |
| Q35054490 | Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy |
| Q37214618 | Bone and brain metastases from ampullary adenocarcinoma |
| Q39398243 | Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells |
| Q48241855 | Brain metastasis from ovarian cancer. |
| Q97532074 | Breast Cancer in Patients 80 Years-Old and Older |
| Q34718428 | Breast cancer in HIV-positive women: a report of four cases and review of the literature |
| Q79887763 | Breast cancer in HIV-positive women: a report of four cases and review of the literature |
| Q37852443 | Breast sarcomas: current and future perspectives |
| Q83350810 | CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy |
| Q92360557 | Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers |
| Q89254199 | Clinical tools for chemotherapy toxicity prediction and survival in geriatric cancer patients |
| Q88499189 | Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer |
| Q44201180 | Cutaneous leukocytoclastic vasculitis associated with letrozole |
| Q48238900 | Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients. |
| Q37610473 | Docetaxel-associated myalgia-arthralgia syndrome in patients with breast cancer |
| Q86664465 | Elevation of Ca19-9 tumor antigen in colorectal cancer: an in silico investigation of pathogenesis |
| Q26770051 | Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation |
| Q35756426 | Eribulin for heavily pre-treated metastatic breast cancer patients |
| Q52730980 | Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications. |
| Q52812641 | Expression of TTF-1 in breast cancer independently of ER expression: A case report and pathogenic implications. |
| Q41847322 | Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy |
| Q48310725 | FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies |
| Q100762764 | Factors influencing psychological wellbeing of early breast cancer patients |
| Q35625631 | Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications |
| Q101052622 | Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets |
| Q33343839 | Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia |
| Q57283292 | HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer |
| Q82742979 | Hand and foot syndrome associated with docetaxel treatment |
| Q91331353 | High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities |
| Q26751021 | Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations |
| Q38994152 | Immune Blockade Inhibition in Breast Cancer |
| Q58737377 | Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers |
| Q47954948 | Immune ligands for cytotoxic T Lymphocytes (CTLS) in cancer stem cells (CSCS). |
| Q42771053 | Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells |
| Q90777862 | Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies |
| Q39192339 | Large cell neuroendocrine carcinoma of the ovary: A pathologic entity in search of clinical identity |
| Q91524401 | Low-grade serous ovarian carcinoma: an evolution toward targeted therapy |
| Q45112779 | Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy. |
| Q38111684 | Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma |
| Q57055619 | Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies |
| Q114173964 | Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors |
| Q39250668 | Molecular predictors of gemcitabine response in pancreatic cancer |
| Q35588786 | NK cells in allogeneic bone marrow transplantation |
| Q91809039 | Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer |
| Q36233076 | Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells |
| Q85024229 | Nonbacterial Thrombotic (Marantic) Endocarditis in a Patient with Colorectal Cancer |
| Q39042616 | Obesity and diabetes as prognostic factors in patients with colorectal cancer |
| Q89034501 | On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer |
| Q42725734 | Orbital metastasis of breast carcinoma |
| Q90259703 | PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review |
| Q28209990 | Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 |
| Q41144730 | Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer |
| Q36894553 | Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis |
| Q42098281 | Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer |
| Q57792353 | Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer |
| Q38390837 | Pluripotency transcription factors in the pathogenesis of colorectal cancer and implications for prognosis |
| Q50103063 | Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer |
| Q37590941 | Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma |
| Q91834493 | Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters |
| Q91849074 | Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor |
| Q92719126 | Prediction of hospital admissions and grade 3-4 toxicities in cancer patients 70 years old and older receiving chemotherapy |
| Q36999374 | Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer |
| Q51595840 | Primary Noncutaneous Malignant Melanoma of the Breast. |
| Q57159896 | Prognostic role of tumor budding in breast cancer |
| Q39201929 | Proteasome expression and activity in cancer and cancer stem cells |
| Q41809067 | Rapid fatal outcome from pulmonary arteries compression in transitional cell carcinoma |
| Q85357378 | Recommendation for omitting axillary lymph node dissection should be individualized in patients with breast cancer with one or two positive sentinel lymph nodes |
| Q43941257 | Streptococcus suis endocarditis and colon carcinoma: a case report |
| Q92593954 | Synchronous tumors of the pancreas and the gallbladder: a case report with targeted NGS evaluation |
| Q42154615 | Targeted treatments for metastatic esophageal squamous cell cancer |
| Q98905941 | The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors |
| Q91943867 | The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center |
| Q53059668 | The chemosensitivity of testicular germ cell tumors. |
| Q104285644 | The landscape of chromosome instability in breast cancers and associations with the tumor mutation burden: An analysis of data from TCGA |
| Q91285434 | The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer |
| Q26785448 | The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer |
| Q55717554 | The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. |
| Q89256163 | The pluripotency network in colorectal cancer pathogenesis and prognosis: an update |
| Q38107999 | The role of ubiquitin-proteasome system in glioma survival and growth |
| Q38134142 | The shaping of invasive glioma phenotype by the ubiquitin-proteasome system |
| Q38029132 | The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer |
| Q37213386 | The ubiquitin-proteasome system in colorectal cancer |
| Q38028002 | The ubiquitin-proteasome system in glioma cell cycle control |
| Q37767875 | The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance |
| Q38190956 | Thrombocytosis as a prognostic marker in gastrointestinal cancers |
| Q34577000 | Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer |
| Q85554027 | Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer |
| Q37991651 | Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer |
| Q38136164 | Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma. |
| Q33839341 | Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series |
| Q100407555 | Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis |
| Q103811802 | Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer |
| Q45262425 | p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer |
Search more.